DocGo to Announce Third Quarter 2024 Results on Thursday, November 7, 2024

10/21/24 7:35:00 AM ET

Medical/Nursing Services

Health Care

Get the next $DCGO alert in real time by email

Management to host conference call and webcast at 5:00 p.m. ET on that day

DocGo Inc. (NASDAQ:DCGO) ("DocGo" or the "Company"), a leading provider of technology-enabled mobile health services, announced today that the Company will release its financial results for the third quarter ended September 30, 2024 after the markets close on Thursday, November 7, 2024. Management will also host a conference call to discuss these results at 5:00 p.m. ET on that day.

Conference call and webcast details:

Thursday, November 7, 2024

5:00 p.m. ET

1-800-717-1738 (U.S.)

1-646-307-1865 (international)

A webcast of the conference call can be accessed under Events on the Investors section of the Company's website at https://ir.docgo.com/.

About DocGo

DocGo is leading the proactive healthcare revolution with an innovative care delivery platform that includes mobile health services, remote patient monitoring and ambulance services. DocGo is helping to reshape the traditional four-wall healthcare system by providing high quality, highly accessible care to patients where and when they need it. DocGo's proprietary technology and relationships with a dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for facilities, hospital networks and health insurance providers. With Mobile Health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment, in tandem with a remote physician, in the comfort of a patient's home or workplace. Together with DocGo's integrated Ambulnz medical transport services, DocGo is bridging the gap between physical and virtual care. For more information, please visit www.docgo.com. To get an inside look on how the proactive healthcare revolution is helping transform healthcare by reducing costs, increasing efficiency and improving outcomes, visit www.proactivecarenow.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241021774796/en/

Get the next $DCGO alert in real time by email

Recent Analyst Ratings for

$DCGO

Date	Price Target	Rating	Analyst
5/9/2025		Buy → Neutral	BTIG Research
2/28/2025	$5.00 → $2.85	Buy → Hold	Deutsche Bank
8/18/2023	$15.00	Buy	BTIG Research
4/21/2023	$11.00	Overweight	Cantor Fitzgerald
4/19/2022	$11.00	Buy	Deutsche Bank
1/19/2022	$14.00	Buy	Stifel
12/21/2021	$13.00	Buy	Canaccord Genuity
12/7/2021	$14.00	Buy	Needham

More analyst ratings

DocGo to Announce Third Quarter 2024 Results on Thursday, November 7, 2024

Chat with this insight

Recent Analyst Ratings for
$DCGO

$DCGO
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Burdiek Michael J bought $13,300 worth of shares (10,000 units at $1.33), increasing direct ownership by 2% to 641,560 units (SEC Form 4)

Director Burdiek Michael J bought $21,450 worth of shares (15,000 units at $1.43), increasing direct ownership by 2% to 631,560 units (SEC Form 4)

Chief Executive Officer Bienstock Lee covered exercise/tax liability with 15,565 shares, decreasing direct ownership by 0.79% to 1,955,514 units (SEC Form 4)

$DCGO
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Burdiek Michael J bought $13,300 worth of shares (10,000 units at $1.33), increasing direct ownership by 2% to 641,560 units (SEC Form 4)

Director Burdiek Michael J bought $21,450 worth of shares (15,000 units at $1.43), increasing direct ownership by 2% to 631,560 units (SEC Form 4)

Director Klasko Stephen K. M.D. bought $22,350 worth of shares (15,000 units at $1.49) (SEC Form 4)

$DCGO
SEC Filings

DocGo Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

DocGo Inc. filed SEC Form 8-K: Regulation FD Disclosure

SEC Form 10-Q filed by DocGo Inc.

DocGo to Announce Third Quarter 2024 Results on Thursday, November 7, 2024

Chat with this insight

Recent Analyst Ratings for $DCGO

$DCGO Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Burdiek Michael J bought $13,300 worth of shares (10,000 units at $1.33), increasing direct ownership by 2% to 641,560 units (SEC Form 4)

Director Burdiek Michael J bought $21,450 worth of shares (15,000 units at $1.43), increasing direct ownership by 2% to 631,560 units (SEC Form 4)

Chief Executive Officer Bienstock Lee covered exercise/tax liability with 15,565 shares, decreasing direct ownership by 0.79% to 1,955,514 units (SEC Form 4)

$DCGO Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Burdiek Michael J bought $13,300 worth of shares (10,000 units at $1.33), increasing direct ownership by 2% to 641,560 units (SEC Form 4)

Director Burdiek Michael J bought $21,450 worth of shares (15,000 units at $1.43), increasing direct ownership by 2% to 631,560 units (SEC Form 4)

Director Klasko Stephen K. M.D. bought $22,350 worth of shares (15,000 units at $1.49) (SEC Form 4)

$DCGO SEC Filings

DocGo Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

DocGo Inc. filed SEC Form 8-K: Regulation FD Disclosure

SEC Form 10-Q filed by DocGo Inc.

Recent Analyst Ratings for
$DCGO

$DCGO
Insider Trading

$DCGO
Insider Purchases

$DCGO
SEC Filings